# A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

Study · id `cardio:ct-nct02625389` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02625389](<https://clinicaltrials.gov/study/NCT02625389>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02625389

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT02625389. Allocation not applicable; no masking; primary purpose treatment. Start 2017-11-29 (actual); primary completion 2021-05-12 (actual). Results posted on 2025-10-10.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Started: 2017-11-29 (actual) (ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Primary completion: 2021-05-12 (actual) (ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Completion: 2021-05-12 (actual) (ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Results first posted: 2025-10-10 (ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Countries: India (ClinicalTrials.gov record NCT02625389, source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02625389-2025-10-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
- Condition: Congenital Hemangioma
- Condition: Hemangioendothelioma
- Condition: Angiosarcoma
- Condition: Arteriovenous Malformations
- Intervention (Drug): Lipiodol Ultra Fluid with surgical glues
- Lead sponsor: Guerbet
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arteriovenous malformation (AVM) (`cardio:arteriovenous-malformation`)
- Registry lists this organization as the lead sponsor: Guerbet (`cardio:org-guerbet`)

## Provenance

Content hash: 9b248e8cf852c1ad6287a03f83459c02cae22b3dc0becf9272d06bebffbce105
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
